NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer cell therapies for oncology and neurodegenerative diseases. The company went public through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Industrial Corp. that completed its IPO in 2021. The merger closed in September 2023, with NKGen filing the associated 8-K on September 29, 2023, under accession number 0001104659-23-105417. The combined company now trades on Nasdaq under the ticker NKGN and operates within the cell therapy segment of the broader biotechnology sector. Sign up for SpacDesk to access the full data profile on NKGN, including filing history, deal timelines, and sponsor intelligence.